What changed: Extrapulmonary neuroendocrine carcinoma
Every dated change on the records linked to Extrapulmonary neuroendocrine carcinoma, newest first: approvals and regulatory steps on its medicines, trials that reported, guideline versions, milestones, and when this page itself was checked. Dates come from the records; none is inferred. Orientation, not medical advice.
Trial result1Milestone7This record1
September 2026 · 1
2026 · 1
2024 · 1
2020 · 2
- 2020Trial resultDART (SWOG S1609): nivolumab plus ipilimumab in rare tumoursDART (SWOG S1609): nivolumab plus ipilimumab in rare tumours reported
Neuroendocrine cohort: about one in four responded, concentrated in high-grade disease; angiosarcoma cohort about one in four, mostly cutaneous scalp and face tumours; many other cohorts inactive.
- 2020MilestoneDART (SWOG S1609): nivolumab plus ipilimumab in rare tumoursDART (SWOG S1609): nivolumab with ipilimumab active in high-grade neuroendocrine carcinoma
A milestone in how this cancer is treated.